Boston [US], April 18 (ANI): For the first time in 50 years, a phase 3 randomised, placebo-controlled trial found that an adjuvant therapy improved overall survival in kidney cancer patients. According to a review of keynote-564 research findings, treating patients with clear-cell renal-cell carcinoma (ccRCC) at high risk for recurrence with pembrolizumab, an immunotherapy medication, […]
English (US) ·